Question 1

What specific benefits do you think I might gain from participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer clinical trial (NCT02608229). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to standard options available for my condition?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer clinical trial (NCT02608229). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer clinical trial (NCT02608229). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatments and check-ups?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer clinical trial (NCT02608229). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects or if my condition worsens during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer clinical trial (NCT02608229). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional tests or procedures I would need to undergo if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer clinical trial (NCT02608229). Contact the study team or your healthcare provider for specific answers.

What this study is about